|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHCR24 |
Gene summary for DHCR24 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHCR24 | Gene ID | 1718 |
| Gene name | 24-dehydrocholesterol reductase | |
| Gene Alias | DCE | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q15392 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1718 | DHCR24 | GSM4909282 | Human | Breast | IDC | 2.21e-13 | 5.60e-01 | -0.0288 |
| 1718 | DHCR24 | GSM4909286 | Human | Breast | IDC | 1.97e-07 | -1.96e-01 | 0.1081 |
| 1718 | DHCR24 | GSM4909290 | Human | Breast | IDC | 6.65e-06 | 3.71e-01 | 0.2096 |
| 1718 | DHCR24 | GSM4909293 | Human | Breast | IDC | 1.40e-04 | 2.67e-01 | 0.1581 |
| 1718 | DHCR24 | GSM4909296 | Human | Breast | IDC | 8.52e-04 | 1.27e-01 | 0.1524 |
| 1718 | DHCR24 | GSM4909298 | Human | Breast | IDC | 2.28e-05 | 2.59e-01 | 0.1551 |
| 1718 | DHCR24 | GSM4909301 | Human | Breast | IDC | 6.02e-08 | 3.87e-01 | 0.1577 |
| 1718 | DHCR24 | GSM4909304 | Human | Breast | IDC | 9.37e-48 | 8.21e-01 | 0.1636 |
| 1718 | DHCR24 | GSM4909307 | Human | Breast | IDC | 7.75e-05 | 3.53e-01 | 0.1569 |
| 1718 | DHCR24 | GSM4909308 | Human | Breast | IDC | 8.31e-19 | 5.25e-01 | 0.158 |
| 1718 | DHCR24 | GSM4909311 | Human | Breast | IDC | 7.99e-24 | 3.34e-01 | 0.1534 |
| 1718 | DHCR24 | GSM4909312 | Human | Breast | IDC | 5.35e-07 | 2.90e-01 | 0.1552 |
| 1718 | DHCR24 | GSM4909319 | Human | Breast | IDC | 7.31e-25 | 2.13e-01 | 0.1563 |
| 1718 | DHCR24 | GSM4909321 | Human | Breast | IDC | 1.23e-05 | 5.88e-02 | 0.1559 |
| 1718 | DHCR24 | brca2 | Human | Breast | Precancer | 5.62e-22 | 4.95e-01 | -0.024 |
| 1718 | DHCR24 | M1 | Human | Breast | IDC | 2.61e-11 | 5.95e-01 | 0.1577 |
| 1718 | DHCR24 | NCCBC2 | Human | Breast | DCIS | 3.22e-08 | 6.78e-01 | 0.1554 |
| 1718 | DHCR24 | P1 | Human | Breast | IDC | 2.75e-06 | 1.74e-01 | 0.1527 |
| 1718 | DHCR24 | P2 | Human | Breast | IDC | 4.62e-02 | 2.09e-01 | 0.21 |
| 1718 | DHCR24 | P3 | Human | Breast | IDC | 2.09e-02 | 5.72e-01 | 0.1542 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
| GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
| GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
| GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
| GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
| GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
| GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
| GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
| GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
| GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
| GO:20001179 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity | 19/1080 | 86/18723 | 3.36e-07 | 1.58e-05 | 19 |
| GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
| GO:00431548 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1080 | 78/18723 | 1.69e-06 | 6.08e-05 | 17 |
| GO:00486087 | Breast | Precancer | reproductive structure development | 43/1080 | 424/18723 | 2.36e-04 | 3.56e-03 | 43 |
| GO:00614587 | Breast | Precancer | reproductive system development | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
| GO:00316393 | Breast | Precancer | plasminogen activation | 6/1080 | 24/18723 | 1.99e-03 | 1.90e-02 | 6 |
| GO:0046661 | Breast | Precancer | male sex differentiation | 19/1080 | 165/18723 | 3.14e-03 | 2.65e-02 | 19 |
| GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
| GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
| GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa001005 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
| hsa0010012 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
| hsa00100 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
| hsa001001 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
| hsa001002 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
| hsa001003 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
| hsa001004 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
| hsa0010011 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHCR24 | SNV | Missense_Mutation | rs760795756 | c.912C>G | p.Phe304Leu | p.F304L | Q15392 | protein_coding | deleterious(0) | possibly_damaging(0.538) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DHCR24 | SNV | Missense_Mutation | rs150166147 | c.736C>T | p.Arg246Trp | p.R246W | Q15392 | protein_coding | tolerated(0.17) | possibly_damaging(0.613) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DHCR24 | SNV | Missense_Mutation | c.989N>A | p.Arg330His | p.R330H | Q15392 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A1B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Adriamycin | SD | |
| DHCR24 | SNV | Missense_Mutation | rs577722198 | c.947N>A | p.Arg316Gln | p.R316Q | Q15392 | protein_coding | tolerated(0.61) | benign(0) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DHCR24 | SNV | Missense_Mutation | c.260N>C | p.Lys87Thr | p.K87T | Q15392 | protein_coding | tolerated(0.06) | possibly_damaging(0.606) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
| DHCR24 | insertion | Nonsense_Mutation | novel | c.235_236insATTTGTATATGTTAACTCATGCATCACTTTGAG | p.Arg79delinsHisLeuTyrMetLeuThrHisAlaSerLeuTerGly | p.R79delinsHLYMLTHASL*G | Q15392 | protein_coding | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| DHCR24 | SNV | Missense_Mutation | rs150166147 | c.736C>T | p.Arg246Trp | p.R246W | Q15392 | protein_coding | tolerated(0.17) | possibly_damaging(0.613) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHCR24 | SNV | Missense_Mutation | rs387906938 | c.307N>T | p.Arg103Cys | p.R103C | Q15392 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DHCR24 | SNV | Missense_Mutation | c.927N>T | p.Glu309Asp | p.E309D | Q15392 | protein_coding | deleterious(0.01) | possibly_damaging(0.787) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DHCR24 | SNV | Missense_Mutation | novel | c.995N>T | p.Thr332Met | p.T332M | Q15392 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1718 | DHCR24 | TUMOR SUPPRESSOR, ENZYME | T-226293 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |